secwatch.observer — SEC 8-K summary
======================================

Issuer:     InspireMD, Inc. (NSPR)
CIK:        0001433607
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001493152-23-039434
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InspireMD Q3 revenue +8.8% to $1.56M; CMS expands CAS coverage; trial results positive
--------------------------------------------------------------------------------

- Q3 revenue $1.556M (+8.8% YoY); gross margin 28.1% (vs 25.6% Q3 2022).
- Net loss $5.178M ($0.15/diluted share) vs $4.529M ($0.58) in Q3 2022; cash $43.0M.
- Positive 30-day C-GUARDIANS IDE results: major adverse events (death/stroke/MI) rate 0.95% at VIVA23.
- CMS final NCD expanded CAS coverage to asymptomatic & standard risk patients, broadening addressable market.
- Leadership additions: Patrick Verta EVP Clinical, Cheryl Tal VP QA/RA; Shane Gleason promoted to CCO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1433607/000149315223039434/0001493152-23-039434-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1433607/000149315223039434/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-039434

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer